EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand
- 200 Downloads
Since 2013, clinical practice guidelines recommend EGFR mutation testing of non-squamous NSCLC to select advanced-stage patients for first-line treatment using EGFR-TKIs.
We aimed to determine population-based trends in the real-world uptake and impact in routine practice of these recently updated testing guidelines.
Patients and Methods
A population-based observational study was conducted of notifications to the New Zealand Cancer Registry of patients eligible for EGFR testing diagnosed in northern New Zealand between January 2010 and April 2014. The main study variable was EGFR mutation testing. Main outcome measures (overall survival and dispensing of EGFR-TKIs) were extracted from prospectively archived electronic databases until October 2015.
The population-based cohort of 1857 patients had an average age of 70 years. Most had adenocarcinoma and metastatic disease at diagnosis. EGFR testing was undertaken in 500 patients (27%) with mutations detected in 109 patients (22%). EGFR testing increased during the period of study from <5% to 67% of patients (P < 0.0001). Full uptake of testing by all eligible patients was limited by a lack of availability of specimens for testing and variable testing referral practices. The proportion of patients treated with EGFR-TKIs decreased during the same time period, both among untested patients (from 12.2% to 2.8% (P < 0.0001)) and in the population as a whole (from 13.7% to 10.6% (P < 0.05)). EGFR testing was associated with prolonged overall survival (Adjusted HR = 0.76 (95% CI, 0.65–0.89) Log-rank P < 0.0001) due at least in part to the much longer overall survival achieved by mutation-positive patients, of whom 79% received EGFR-TKIs. Compared to untested EGFR-TKI-treated patients, mutation-positive EGFR-TKI-treated patients received EGFR-TKIs for longer, and survived longer both from the start of EGFR-TKI treatment and date of their diagnosis.
In this real world setting, high uptake of EGFR testing was achieved and associated with major changes in EGFR-TKI prescribing and improved health outcomes. Modifiable factors determined testing uptake.
We thank the many patients who contributed to this study. Maria Luisa Bituin contributed to the data collection. We thank the Health Research Council of New Zealand for their grant funding support (Project grants 13/981 and 15/087). Sandar Tin Tin was supported by the Auckland Medical Research Foundation/Perpetual David and Cassie Anderson Postdoctoral Fellowship and Kelliher Charitable Trust Emerging Researcher Start-up Award.
Compliance with Ethical Standards
The research was supported by grants from the Health Research Council of New Zealand (grant numbers 13/981 and 15/087).
Conflict of Interest
The authors report no conflicts of interest.
- 2.Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–59.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–9.CrossRefPubMedGoogle Scholar
- 6.Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.CrossRefPubMedGoogle Scholar
- 8.Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.CrossRefPubMedGoogle Scholar
- 9.Wu Y-L, Zhou C, Liam C-K, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–9.CrossRefPubMedGoogle Scholar
- 10.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877–83.CrossRefPubMedGoogle Scholar
- 11.Zhou CC, Wu YL, Chen GY, Feng JF, Liu XQ, Wang CL, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.CrossRefPubMedGoogle Scholar
- 21.Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by Erlotinib in a French prospective cohort (ERMETIC project-part 2). J Thorac Oncol. 2012;7(10):1490–502.CrossRefPubMedGoogle Scholar
- 22.Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387(10026):1415–26.CrossRefPubMedGoogle Scholar
- 23.Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian Tertiary Hospital. PLoS One. 2013;8(2) doi: 10.1371/journal.pone.0056011.
- 28.Lynch JA, Khoury MJ, Borzecki A, Cromwell J, Hayman LL, Ponte PR, et al. Epidermal growth factor receptor (EGFR) test utilization in the United States: a case study of T3 translational research. Genet Med. 2013;15(8):630–8.Google Scholar
- 29.Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. Plos One. 2016;11(6) doi: 10.1371/journal.pone.0156728.
- 31.Schuette W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Mezger J, et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1254–61.Google Scholar
- 32.Anonymous. Cancer new registrations and deaths 2011. Wellington: Ministry of Health; 2014.Google Scholar
- 35.Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of Tumours. Pathology and Genetics of Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.Google Scholar
- 36.Salmond C, Crampton P, Atkinson J. NZDep2006 index of deprivation. Wellington: Department of Public Health, University of Otago; 2007.Google Scholar
- 37.Anonymous. New Zealand: an urban/rural profile. Wellington: Statistics New Zealand; 2007.Google Scholar
- 39.O’Donnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J, et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013;13:210.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Santos GC, Lai SW, Saieg MA, Geddie WR, Pintilie M, Tsao M-S, et al. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. Lung Cancer. 2012;77(3):501–6.CrossRefGoogle Scholar
- 46.Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–8.CrossRefPubMedGoogle Scholar
- 47.Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981–8.Google Scholar
- 48.Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology research group (HORG) randomized phase 3 study. Cancer. 2013;119(15):2754–64.CrossRefPubMedGoogle Scholar
- 49.Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13(11):1161–70.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, et al. How molecular understanding affects to prescribing patterns and clinical outcome of Gefitinib in non-small cell lung cancer? 10 year experience of single institution. Cancer Res Treat. 2013;45(3):178–85.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, et al. EGFR mutations predict survival benefit from Gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after Gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589–95.CrossRefPubMedGoogle Scholar
- 55.Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y, et al. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. Plos One. 2014;9(8) doi: 10.1371/journal.pone.0106053.